Association of calcium channel blockers and mortality in haemodialysis patients

Clinical Science

Volumn 103, Issue 5, 2002, Pages 511-515

  Tepel, Martin ^a   Van der Giet, Markus ^a   Park, Alexander ^a   Zidek, Walter ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Calcium channel blockers; End stage renal failure; Haemodialysis; Mortality

Indexed keywords

BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ERYTHROPOIETIN;

ADULT; AGED; ARTERY CALCIFICATION; ARTICLE; BODY MASS; CALCIUM METABOLISM; CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; CAUSE OF DEATH; CONTROLLED STUDY; FEMALE; HEART DEATH; HEMODIALYSIS; HUMAN; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; REGRESSION ANALYSIS; RISK ASSESSMENT; SURVIVAL RATE; TREATMENT OUTCOME;

EID: 0036844977     PISSN: 01435221     EISSN: None     Source Type: Journal    
DOI: 10.1042/cs1030511     Document Type: Article

References (35)

1. Mallick, N. P. and Gokal, R. (1999) Haemodialysis. Lancet 353, 737-742
2. Pastan, S. and Bailey, J. (1998) Dialysis therapy. N. Engl. J. Med. 338, 1428-1437
3. Parfrey, P. S. (2000) Cardiac disease in dialysis patients: Diagnosis, burden of disease, prognosis, risk factors and management. Nephrol. Dial. Transplant. 15 (Suppl. 5), 58-68
4. Locatelli, F., Marcelli, D., Conte, F. et al. (2000) Cardiovascular disease in chronic renal failure: The challenge continues. Nephrol. Dial. Transplant. 15 (Suppl. 5), 69-80
5. Goldwasser, P., Mittman, N., Antignani, A. et al. (1993) Predictors of mortality in hemodialysis patients. J. Am. Soc. Neprol. 3, 1613-1622
6. Charra, B., Calemard, E. and Laurent, G. (1996) Importance of treatment time and blood pressure control in achieving long-term survival on dialysis. Am. J. Nephrol. 16, 35-44
7. Bianchi, G. (2000) Hypertension in chronic renal failure and end-stage renal disease patients treated with hemodialysis or peritoneal dialysis. Nephrol. Dial. Transplant. 15 (Suppl. 5), 105-110
8. Tepel, M., Echelmeyer, M., Orie, N. N. and Zidek, W. (2000) Increased intracellular reactive oxygen species in patients with end-stage chronic renal failure: Effect of hemodialysis. Kidney Int. 58, 867-872
9. Baigent, C., Burbury, K. and Wheeler, D. (2000) Premature cardiovascular disease in chronic renal failure. Lancet 356, 147-152
10. Herzog, C. A., Ma, J. Z. and Collins, A. J. (1998) Poor long-term survival after acute myocardial infarction among patients on long-term dialysis. N. Engl. J. Med. 339, 799-805
11. Owen, W. F., Lew, N. L., Liu, Y., Lowrie, E. G. and Lazarus, J. M. (1993) The urea reduction ratio and serum albumin concentration as predictors of mortality in patients undergoing hemodialysis. N. Engl. J. Med. 329, 1001-1006
12. Iseki, K., Kawazoe, N. and Fukiyama, K. (1993) Serum albumin is a strong predictor of death in chronic dialysis patients. Kidney Int. 44, 115-119
13. Amann, K., Gross, M. L., London, G. M. and Ritz, E. (1999) Hyperphosphataemia - A silent killer of patients with renal failure. Nephrol. Dial. Transplant. 14, 2085-2087
14. Block, G. A., Hulbert-Shearon, T. E., Levin, N. W. and Port, F. K. (1998) Association of serum phosphorus and calcium x phosphate product with mortality risk in chronic hemodialysis patients: A national study. Am. J. Kidney Dis. 31, 607-617
15. Marchais, S. J., Metivier, F., Guerin, A. P. and London, G. M. (1999) Association of hyperphosphataemia with haemodynamic disturbances in end-stage renal disease. Nephrol. Dial. Transplant. 14, 2178-2183
16. Braun, J., Oldendorf, M., Moshage, W., Heidler, R., Zeitler, E. and Luft, F. C. (1996) Electron beam computed tomography in the evaluation of cardiac calcification in chronic dialysis patients. Am. J. Kidney Dis. 27, 394-401
17. Goodman, W. G., Goldin, J., Kuizon, B. D. et al. (2000) Coronary-artery calcification in young adults with end-stage renal disease who are undergoing dialysis. N. Engl. J. Med. 342, 1478-1483
18. Blood Pressure Lowering Treatment Trialists' Collaboration (2000) Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: Results of prospectively designed overviews of randomised trials. Lancet 355, 1955-1964
19. Conlin, P. R. and Williams, G. H. (1998) Use of calcium channel blockers in hypertension. Adv. Intern. Med. 43, 533-562
20. World Health Organization (1999) International Society of Hypertension guidelines for the management of hypertension. J. Hypertens. 117, 151-183
21. Luft, F. C. and Johnston, C. I. (1992) Are calcium antagonists of value in ameliorating the course of chronic renal disease? Kidney Int. 41 (Suppl. 36), S114-S118
22. Wright, B., Zeidmann, I., Greig, R. and Poste, G. (1985) Inhibition of macrophage proliferation by calcium channel blockers and calmodulin antagonists. Cell. Immunol. 95, 46-53
23. i and proliferation of B cells from dialysis patients. Kidney Int. 50, 1249-1254
24. Mutoh, S., Nomoto, A., Sekiguchi, C. and Yamaguchi, I. (1988) Protective action of calcium antagonist, nilvadipine, against aortic deposition - A pathogenic factor in atherosclerosis. Atherosclerosis 73, 181-189
25. Fleckenstein-Grün, G., Thimm, F., Frey, M. and Matyas, S. (1995) Progression and regression by verapamil of vitamin D3-induced calcific medial degeneration in coronary arteries of rats. J. Cardiovasc. Pharmacol. 26, 207-213
26. Leavey, S. F., Strawderman, R. L., Jones, C. A., Port, F. K. and Held, P. J. (1998) Simple nutritional indicators as independent predictors of mortality in hemodialysis patients. Am. J. Kidney Dis. 29, 997-1006
27. Staessen, J. A., Fagard, R., Thijs, L. et al. (1997) Randomised double-blind comparison of placebo and active treatment for older patients with isolated systolic hypertension. The Systolic Hypertension in Europe (Syst-Eur) Trial. Lancet 350, 757-764
28. Pitt, B., Byington, R. P., Furberg, C. D. et al. (2000) Effect of amlodipine on the progression of atherosclerosis and the occurence of clinical events. PREVENT Investigators. Circulation 102, 1503-1510
29. Brown, M. J., Palmer, C. R., Castaigne, A. et al. (2000) Morbidity and mortality in patients randomised to double-blind treatment with a long-acting calcium-channel blocker or diuretic in the International Nifedipine GITS study: Intervention as a goal in hypertension treatment. Lancet 356, 366-372
30. Hansson, L., Hedner, T., Lund-Johansen, P. et al. (2000) Randomised trial of effects of calcium antagonists compared with diuretics and beta-blockers on cardiovascular morbidity in hypertension: The Nordic Diltiazem (NORDIL) study. Lancet 356, 359-365
31. Motro, M. and Shemesh, J. (2001) Calcium channel blocker nifedipine slows down progression of coronary calcification in hypertensive patients compared with diuretics. Hypertension 37, 1410-1413
32. Furberg, C. D., Psaty, B. M. and Meyer, J. V. (1995) Nifedipine: Dose-related increase in mortality in patients with coronary heart disease. Circulation 92, 1326-1331
33. Estacio, R. O., Jeffers, B. W., Hiatt, W. R., Biggerstaff, S. L., Gifford, N. and Schrier, R. W. (1998) The effect of nisoldipine as compared with enalapril on cardiovascular outcomes in patients with non-insulin-dependent diabetes and hypertension. N. Engl. J. Med. 338, 645-652
34. Pahor, M., Psaty, B. M., Alderman, M. H. et al. (2000) Health outcomes associated with calcium antagonists compared with other first-line antihypertensive therapies: A meta-analysis of randomised controlled trials. Lancet 356, 1949-1954
35. Kestenbaum, B., Gillen, D. L., Sherrard, D. J., Seliger, S., Ball, A. and Stehman-Breen, C. (2002) Calcium channel blocker use and mortality among patients with end-stage renal disease. Kidney Int. 61, 2157-2164